Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

809126

	registered interest
	date	19/12/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	What estimate he has made of the number of patients with Erythropoietic Protoporphyria.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	903031
	answer	answer is ministerial correction date of answer 19/12/2017 answer text <p>In 2016/17 there were 54 National Health Service admissions in England with a primary diagnosis of Erythropoietic Protoporphyria.</p><p> </p><p>Whilst the numbers of people with a particular rare disease can be very small, 3.5 million people in the United Kingdom have a rare disease. We know, as with the hon. Member’s constituent, that these diseases can have a heart-breaking impact on a person’s health.</p><p> </p><p>That‘s why the UK is committed to building on our position as a world-leader in the diagnosis and treatment of rare diseases.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/12/2017 17:07:30 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden

938539

	registered interest
	date	11/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Erythropoietic Protoporphyria
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to support people diagnosed with Erythropoietic Protoporphyria as a result of the decision by NICE not to license Scenesse.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	163053
	answer	answer is ministerial correction date of answer 16/07/2018 answer text <p>We have had no such discussions with patients with erythropoietic protoporphyria. The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of afamelanotide for treating erythropoietic protoporphyria. NICE’s final draft guidance, published in May 2018, is currently subject to an appeal lodged by the drug manufacturer and other bodies. The appeal is due to be heard by NICE’s appeal panel on 30 July.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 163054 question first answered 16/07/2018 16:09:17 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden

896484

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of women who have moved to Wales who may not have been invited to their final breast screening as a result of the computer failure in the national breast screening programme in England.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	140672
	answer	answer is ministerial correction date of answer 09/05/2018 answer text <p>NHS Digital is working with all the devolved administrations to reconcile their respective record to trace the women affected. Once identified, Public Health England will send the appropriate letter to each of the identified women by the end of May 2018.</p><p> </p><p>No assessment has been made on the number of women who have moved to Wales and may not have been invited to their final breast screening. NHS Digital is working with all devolved administrations to reconcile the record to confirm a number.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140671 question first answered 09/05/2018 10:39:16 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden

938683

	registered interest
	date	11/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Erythropoietic Protoporphyria
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with people diagnosed with Erythropoietic Protoporphyria on the decision by NICE not to license Scenesse for availability on the NHS.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	163054
	answer	answer is ministerial correction date of answer 16/07/2018 answer text <p>We have had no such discussions with patients with erythropoietic protoporphyria. The National Institute for Health and Care Excellence (NICE) has not yet published final guidance on the use of afamelanotide for treating erythropoietic protoporphyria. NICE’s final draft guidance, published in May 2018, is currently subject to an appeal lodged by the drug manufacturer and other bodies. The appeal is due to be heard by NICE’s appeal panel on 30 July.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 163053 question first answered 16/07/2018 16:09:17 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden

896483

	registered interest
	date	02/05/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how his Department intends to contact women who have moved to Wales who may not have been invited to their final breast screening due to computer failure as identified in the national breast screening programme in England; and what the timetable is for contacting those people.
	tabling member constituency	Newport East
	tabling member printed	Jessica Morden
	uin	140671
	answer	answer is ministerial correction date of answer 09/05/2018 answer text <p>NHS Digital is working with all the devolved administrations to reconcile their respective record to trace the women affected. Once identified, Public Health England will send the appropriate letter to each of the identified women by the end of May 2018.</p><p> </p><p>No assessment has been made on the number of women who have moved to Wales and may not have been invited to their final breast screening. NHS Digital is working with all devolved administrations to reconcile the record to confirm a number.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 140672 question first answered 09/05/2018 10:39:16 answering member 4067 label Biography information for Steve Brine
	tabling member	1548 label Biography information for Jessica Morden